All In MedTech

FDA Clearance Tracker · P010012-S550

Contak CD, Easytrak, Livian, Cognis and Acuity Spirial Automatic Implantable Cardiac Resynchronization Therapy Defibrill

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 4, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 4, 2022

Approved

Time to decision

30 days

Received Feb 2, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P010012-S550
Device name
Contak CD, Easytrak, Livian, Cognis and Acuity Spirial Automatic Implantable Cardiac Resynchronization Therapy Defibrill
Applicant location
St Paul, MN
Received
Feb 2, 2022
Decided
Mar 4, 2022
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P010012

Device type

Device class
Class III

Every decision under product code NIK

FDA's approval statement

As written in FDA's record.

Approval to suspend enrollment for six (6) months for MANAGE-HF.

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.